Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 1,230.7% in February

Chemomab Therapeutics Ltd. (NASDAQ:CMMBGet Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 389,900 shares, a growth of 1,230.7% from the February 13th total of 29,300 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average trading volume of 336,300 shares, the short-interest ratio is currently 1.2 days.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock opened at $1.38 on Friday. The company has a market capitalization of $19.74 million, a P/E ratio of -1.37 and a beta of 0.54. The company’s 50 day moving average price is $1.88 and its two-hundred day moving average price is $1.74. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55.

Institutional Trading of Chemomab Therapeutics

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Chemomab Therapeutics during the 4th quarter worth approximately $26,000. XTX Topco Ltd raised its holdings in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in Chemomab Therapeutics during the 3rd quarter worth approximately $1,907,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CMMB shares. Oppenheimer reiterated an “outperform” rating and issued a $11.00 price target (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th. Maxim Group increased their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, February 20th.

Read Our Latest Stock Analysis on Chemomab Therapeutics

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Featured Articles

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.